Theravance Biopharma Inc (TBPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theravance Biopharma Inc (TBPH) has a cash flow conversion efficiency ratio of -0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.06 Million) by net assets ($296.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TBPH company net worth for the company's overall valuation and market capitalisation.
Theravance Biopharma Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Theravance Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Theravance Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theravance Biopharma Inc ranked by their cash flow conversion efficiency. Explore Theravance Biopharma Inc (TBPH) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bangkok Chain Hospital Public Company Limited
BK:BCH
|
0.050x |
|
Blue Sail Medical Co Ltd
SHE:002382
|
-0.007x |
|
China West Construction Group Co Ltd
SHE:002302
|
-0.013x |
|
Aeva Technologies, Inc. Common Stock
NASDAQ:AEVA
|
2.083x |
|
WAVE LIFE SCIENCES LTD.
F:1U5
|
-0.116x |
|
Shanghai Anoky Group
SHE:300067
|
-0.006x |
|
InMode Ltd
NASDAQ:INMD
|
0.033x |
|
Guangzhou Pearl River Piano Group Co Ltd
SHE:002678
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Theravance Biopharma Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Theravance Biopharma Inc from 2011 to 2025. View Theravance Biopharma Inc (TBPH) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $296.72 Million | $238.54 Million | 0.804x | +1323.44% |
| 2024-12-31 | $175.54 Million | $-11.54 Million | -0.066x | +48.16% |
| 2023-12-31 | $213.00 Million | $-27.00 Million | -0.127x | +70.05% |
| 2022-12-31 | $441.80 Million | $-186.99 Million | -0.423x | -168.94% |
| 2021-12-31 | $-338.57 Million | $-207.86 Million | 0.614x | -25.53% |
| 2020-12-31 | $-303.75 Million | $-250.40 Million | 0.824x | -22.53% |
| 2019-12-31 | $-223.84 Million | $-238.20 Million | 1.064x | -51.36% |
| 2018-12-31 | $-51.59 Million | $-112.87 Million | 2.188x | +225.33% |
| 2017-12-31 | $115.18 Million | $-201.05 Million | -1.746x | -517.60% |
| 2016-12-31 | $350.23 Million | $-98.99 Million | -0.283x | +59.31% |
| 2015-12-31 | $243.06 Million | $-168.86 Million | -0.695x | -14.94% |
| 2014-12-31 | $289.79 Million | $-175.16 Million | -0.604x | -108.51% |
| 2013-12-31 | $-17.04 Million | $-120.96 Million | 7.101x | -89.81% |
| 2012-12-31 | $-1.71 Million | $-119.11 Million | 69.653x | +11648.91% |
| 2011-12-31 | $-140.72 Million | $-83.43 Million | 0.593x | -- |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic n… Read more